LARSEN-&-TOUBRO-INFOTECH
6.2.2020 12:02:04 CET | Business Wire | Pressemeddelelse
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), er en global virksomhed inden for teknologirådgivning og digitale løsninger, har udvidet sin aftale med OKQ8 AB Scandinavia. I løbet af de næste fem år vil denne aftale tranformere applikationer og OKQ8’s infrastruktur landskab med tjenester der omfatter Infrastruktur-as-a-Service (IaaS), Sikkerhedstjenester, Applikationsdrift, Vedligeholdelse og Udvikling, hvilket vil resultere i forbedret stabilitet, tilgængelighed og forudsigelighed af it-driften.
OKQ8, der har hovedkvarter i Stockholm, er en af Skandinaviens største brændstofvirksomheder med en omsætning på over 39 mia. SEK og tæt på 1000 stationer over hele Danmark og Sverige. LTI har været partner med OKQ8 siden 2017, og denne udvidede aftaler er et resultat af, hvad dette partnerskab har skabt gennem årene. Som en strategisk partner vil LTI udnytte sine omfattende evner indenfor analyse, automatisering og KI til at levere disse servicer til OKQ8.
Mikael Pålsson, CIO, OKQ8 , udtaler, “For at kunne betjene vores kunder bedre er det afgørende for OKQ8 at integrere vores økosystem som består af brændstofstationer, dagligvarebutikker, bilvaske, biludlejninger samt økonomi- og forsikringsservicer. Som vores strategiske partner bringer LTI den rette erfaring, teknologiske kompetence og kulturelle tilpasning der sikrer, at dette program bliver en fuldkommen succes.”
Arun Sankaranarayanan, Chief Business Officer, LTI Nordics , udtaler, “Siden begyndelsen I 1999 har OKQ8 konsekvent sat høje standarder for teknologiudnyttelse og ekspertise indenfor kundeservice. Vi er glade for at udvide vores partnerskab med OKQ8 for at designe næste generations arkitektur og opfylde virksomhedens vision for digital transformation. LTI vil udnytte sine evner indenfor eksponentielle teknologier og kundecentrisk tilgang til at hjælpe OKQ8 med at nå sine strategiske mål.”
LTI har en stærk tilstedeværelse I hele Norden og samarbejder med førende virksomheder for at hjælpe dem med at konkurrere effektivt i en verden i forandring.
Om LTI:
LTI (NSE: LTI) er en global virksomhed inden for teknologirådgivning og digitale løsninger, der hjælper over 420 klienter med at få succes i en konvergerende verden. Med operationer I 32 lande går vi den ekstra mil for vores klienter og fremskynder deres digitale transformation med LTIs Mosaic platform, som muliggør deres mobile, sociale, analytiske, IoT og cloud-baserede rejser. Vi blev grundlagt I 1997 som et datterselskab af Larsen & Toubro Limited, og vores unikke arv giver os en uovertruffen ekspertise til at løse de mest komplekse udfordringer for virksomheder på tværs af alle brancher. Hver dag giver vores team, på over 30.000 LTI-medarbejdere, vores kunder mulighed for at forbedre effektiviteten af deres forretnings- og teknologidrift samt levere værdi til deres kunder, medarbejdere og aktionærer. Læs mere på http://www.Lntinfotech.com eller følg os på @LTI_Global
Om OKQ8 AB :
OKQ8 Scandinavia: Den foretrukne mulighed for bæredygtig bevægelse
OKQ8 Scandinavia har operationer I Sverige og Danmark og er en af Skandinaviens største brændstofvirksomheder. Vi er en organisation med omkring 5000 ansatte som er engagerede, kundeorienterede og har fokus på bæredygtighed. Vi arbejder aktivt på at drive udviklingen af mere klima- og miljøvenlige brændstoffer og produkter fremad, på at reducere ulighed og på at bidrage til bæredygtige byer og samfund. Med omkring 1000 servicestationer, vores egen bank og et af markedets stærkeste virksomhedstilbud ønsker vi at være den foretrukne mulighed for bæredygtig forretning – både nu og i fremtiden. Læs mere på www.okq8.se
Forbind til LTI:
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200206005412/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
